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Background: Psoriatic Arthritis (PsA) is estimated to occur in 10-15% of people with psoriasis and accounts for 13%
of people attending early arthritis clinics. With an increasing awareness of the poor outcomes associated with PsA
and the availability of new effective, but costly, treatments, there is an urgent need to research the optimal
treatment for patients with PsA. The aim of the TICOPA study is to establish whether, in treatment naive early PsA
patients, “tight control” intensive management with protocol driven therapies and pre-defined objective targets for
treatment can improve clinical outcome compared to standard care alone.
Methods/design: TICOPA is a UK multicentre, open-label, randomised controlled, parallel group trial of 206 patients
with early PsA. Patients will be randomised on a 1:1 basis to receive either standard care (12 weekly review) or
intensive management (4 weekly review) for a period of 48 weeks. Patients assigned to the intensive management
group will follow a strict treatment protocol whereby dose continuation/escalation is determined through the
objective assessment of the minimal disease activity (MDA) criteria. Patients assigned to the standard care group
will have treatment prescribed as felt appropriate by the treating clinician, with no set protocol. The primary
objective of the trial is to compare intensive management with standard care in terms of the proportion of patients
achieving an ACR 20 response at 48 weeks post-randomisation, in order to determine whether intensive
management has superior clinical efficacy. Key secondary outcomes include ACR 50 and 70, PASI 75 and X-ray Van
der Heijde score at 48 weeks post-randomisation along with cost-effectiveness at 12, 24 and 28 weeks.
Discussion: The TICOPA trial will provide direct evidence as to whether the use of early and intensive treatment in
PsA in routine clinical care leads to an improvement in patients’ disease activity and a reduction in radiological joint
damage.
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Psoriatic arthritis (PsA) is estimated to occur in 10-15%
of people with psoriasis and accounts for 13% of people
attending early arthritis clinics [1]. Two thirds of people
with PsA suffer progressive joint damage, increasing
disability and reduced life expectancy [1-3]. With in-
creasing awareness of these poor outcomes and the
availability of new effective but costly treatments, there
is an urgent need to research the optimal treatment for
patients with PsA.
Research in rheumatoid arthritis (RA) has identified
the strong link between inflammation and subsequent
joint damage with modern imaging [4]. Subsequently the
TIght COntrol of RA (TICORA) study introduced the
concept of “tight control” where pre-defined disease ac-
tivity levels guide therapeutic changes for RA patient
management. TICORA demonstrated that tight control
of disease resulted in significantly better clinical and
radiographic outcomes compared to routine care with
no formal therapeutic protocol [5].
There is little research into the link between inflam-
mation and structural joint damage in PsA. Previous
cohort studies in established disease have shown that ac-
tive swollen joints and previous joint damage are predic-
tors of a future increase in the clinically damaged joint
count [6] and radiological progression [7]. The potential
for imaging studies to aid understanding of the patho-
genesis of PsA is well recognised [8], but there has been
very little work done using modern imaging in PsA, es-
pecially in early disease, to improve mechanistic insight
into the disease. There is no research in PsA addressing
the concept of tight control of inflammation to reduce
joint damage.
Studies in RA using tight control aim for pre-specified
low Disease Activity Scores (DAS), and have shown im-
proved disease outcomes [5]. The TICORA study identi-
fied the benefit of tight control even before the use
of newer biologic agents. This work has led to a shift in
the attitudes seen in routine clinical care with further
emphasis placed on disease control to prevent further
damage. The use of objective outcome measures such as
DAS to guide treatment is now becoming routine in
clinical care. Research has also continued from this
stance with emphasis on early treatment and achieving
remission in the care of patients with RA. However, the
DAS was developed for RA and is not ideal for use in
PsA because it fails to take into account the unique as-
pects of the disease, and because cut off points for levels
of disease activity have never been validated. In RA,
there is only one available objective target that does not
rely on composite scoring; this is the OMERACT (Out-
come Measures in Rheumatology group) definition of
minimal disease activity (MDA), which is defined as “a
state which is deemed a useful target of treatment byboth physician and patient, given current treatment pos-
sibilities and limitations” [9]. These criteria are based on
the OMERACT core set of domains for RA [9].
A core set of domains for PsA has now also been
agreed by OMERACT [10], and new criteria to define
disease activity in PsA have now been developed [11].
These criteria for MDA incorporate measures of joint
and entheseal inflammation, skin disease, patient re-
ported outcomes and functional ability to assess the pa-
tient’s disease activity. These criteria were developed
with support from the Group for Research and Assess-
ment of Psoriasis and Psoriatic Arthritis (GRAPPA),
an international research consortium for PsA and psor-
iasis. They have been preliminarily validated using the
OMERACT filter with data from independent observa-
tional cohorts and interventional trial datasets [12,13].
These data have shown that the MDA criteria represent
the concept of MDA accurately, have an ability to differ-
entiate and prognosticate, and are feasible in clinical
practice.
From observational data in PsA, it seems likely that
there is a link between inflammation and damage; mod-
ern imaging should clarify this situation. Suppression of
inflammation using new biological therapies has im-
proved outcomes for people with established PsA. How-
ever, there are no therapeutic trials assessing treatment
in the early stages of disease before significant joint
damage has occurred. The therapeutic concept of “tight
control” has never been investigated in PsA despite the
fact that this is well established as the optimal treatment
in early RA. Combining these concepts of early treat-
ment and tight control of inflammation in a therapeutic
trial could further elucidate the role of inflammation and
establish the optimal treatment for people with PsA.
With the development and validation of the MDA cri-
teria, a disease specific target for treatment has been
established in PsA and the use of the principles of tight
control that were used in the TICORA study can now be
applied to patients with PsA. The aim of the study is to
utilise the MDA criteria in a tight control protocol to
treat newly diagnosed PsA. The TICOPA study will gen-
erate mechanistic evidence to inform whether there is a
link between inflammation and damage and provide per-
tinent knowledge of the benefit of intensive treatment to
provide superior clinical care to patients with PsA and a
consequent landmark shift in clinical management simi-
lar to that observed in RA resulting in part from the
TICORA study.
Methods
Study aims
The aims of the TICOPA study are to compare the clinical
and imaging outcomes over 48 weeks, and safety out-
comes over 52 weeks after commencement of therapy in
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“tight control” protocol-led treatment or usual clinical
care. The principle hypothesis is that tight control of in-
flammation in PsA will lead to an improvement in pa-
tients’ disease activity and a reduction in radiological
damage compared to standard care alone.Primary objective
To compare intensive management to standard care in
terms of the proportion of patients achieving an ACR20
response at 48 weeks post-randomisation, in order to de-
termine whether intensive management has superior
clinical efficacy.Secondary objectives
To compare intensive management with standard care
in terms of additional clinical efficacy outcomes at 24
and 48 weeks, including:
 ACR20 (24 weeks), ACR50 and ACR70
 PASI 50, PASI 75 and PASI 90
 Change in Sharp-van der Heijde Score
 Assessment of cost effectiveness at 12, 24 and 48
weeks
 ASAS 20 and ASAS 40
 Change in enthesitis score
 Change in dactylitis score
 Change in mNAPSI
 Change in HAQ
 Change in other scores (including BASDAI, tender
and swollen joint counts, patient and clinician VAS
scores)
 MDA score
 Comparison of Quality of Life (QoL),using PsAQoL
between intensive management and standard care at
baseline, 24 and 48 weeks
 Comparison of safety outcomes over the course of
the treatment until 52 weeks
 Comparison of imaging efficacy outcomes including
change in Psoriatic Arthritis Magnetic Resonance
Imaging Score (PsAMRIS) and ultrasound
assessment of disease at 48 weeks in order to assess
inflammation and damage (sub-study).Study design
The TICOPA trial is designed as a randomised, con-
trolled, parallel group, open label, multi-centre clinical
trial of 206 patients with recent onset psoriatic arthritis.
Patients will be randomised on a 1:1 basis to receive
either standard care (12 weekly review) or tight control
(4 weekly review) for a period of 48 weeks, with follow-
up of safety up to 52 weeks.Study interventions
Patients assigned to the intensive group will be seen
every 4 weeks by the study physician. A strict treatment
protocol (see Figure 1) is followed for treatment. At each
visit, the minimal disease activity (MDA) criteria [11] are
assessed. These criteria include assessment of the follow-
ing: (i) a full 68 tender and 66 swollen joint count, (ii)
Psoriasis Area Severity Index (PASI), (iii) enthesitis
count, (iv) patient global disease activity VAS, (v) patient
pain VAS, and (vi) the Health Assessment Questionnaire
(HAQ). Treatment with DMARDs is escalated to the
maximum dose according to the protocol in Figure 1 if
patients do not achieve the MDA criteria. In the case of
drug intolerance, that drug is discontinued and the next
step in the protocol is initiated. Any patient who cannot
tolerate the maximum dose specified in the protocol due
to toxicity or intolerance, is permitted to continue on
the highest tolerable dose and then progress to the next
step in the protocol if required. Patients achieving these
criteria will continue on their current therapy. Intra-
articular and intra-muscular steroids are also used in
disease control. Patients are offered local joint injections
to active joints and/or intramuscular steroid by the phy-
sicians if considered appropriate.
Patients randomised to the standard therapy group are
treated in a general rheumatology outpatient clinic su-
pervised by a consultant rheumatologist and including
trainee rheumatologists working under supervision. These
participants are reviewed every 12 weeks or more often if
clinically indicated, with no formal measures of disease
activity used in clinical decision making. There is no re-
quirement or restriction on prescribing within this arm of
the study.
Recruitment
A total of 206 patients will be recruited over a period of
46 months. Eligible patients will be identified from early
arthritis clinics and new referrals to rheumatology clinics
at eight hospital sites in the UK. Each site will receive an
initiation visit by the member of the research team who
will fully train local collaborators in the study.
Patients with a consultant diagnosis of psoriatic arth-
ritis less than two years duration will be recruited. Eligi-
bility for the study is determined at a clinical screening
visit with a rheumatologist and research nurse. The
study team will ensure that the patient satisfies the study
inclusion criteria and does not have any of the exclusion
criteria listed in Table 1.
Patients will be approached during standard clinic
visits and will be provided with a detailed Patient Infor-
mation Sheet. They will also be provided with a verbal
explanation of the trial by the attending medical staff.
Patients will be given at least 24 hours to read the infor-
mation to consider participation. Assenting patients will
Figure 1 TICOPA Study Flow Diagram.
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provide written informed consent.
Eligible patients participating in the Yorkshire region
will be invited to take part in the optional imaging sub-
study based in Leeds. Verbal information and a separate
Patient Information Sheet will again be provided for the
imaging sub-study. Patients will then be invited to pro-
vide separate written informed consent for this sub-
study.
Non- randomised patients
Participating research sites will be required to complete
a log of all patients, over the age of 18 years with PsA
screened for eligibility who are not randomised either
because they are ineligible or because they decline par-
ticipation. Anonymised information collected includes
age, gender, ethnicity, reason not eligible for trial partici-
pation or for declining participation despite eligibility.
Randomisation
Following confirmation of eligibility and written in-
formed consent and completion of baseline assessments
and questionnaires, patients will be randomised. Ran-
domisation will be performed by an authorised memberof staff at the research site. Patients will be randomised
on a 1:1 basis to receive either intensive management or
standard care. Randomisation will be performed using
minimisation, incorporating a random element, via a cen-
tral 24-hour automated telephone randomisation system
based at the Leeds Clinical Trials Research Unit. The
dynamic allocation method should ensure treatment
groups are balanced for randomising centre and pattern of
arthritis (oligoarticular vs polyarticular).
Pre-treatment investigations
At screening a chest X-ray (CXR) will be performed un-
less a CXR is available for the patient within the previ-
ous 6 months, and this will be checked prior to starting
on treatment with methotrexate. If patients are to be
prescribed any of the anti-TNF therapies (etanercept,
infliximab, adalimumab) then standard screening will
apply. Screening for TB will include either a negative
Mantoux test or a negative QuantiFERON gold or TB
Spot test. In the event of a positive or borderline test,
the test is repeated. If this remains borderline or posi-
tive, patients are treated with TB prophylaxis (isoniazid
300mg po od and pyridoxine 100mg po od) for a mini-
mum of 2 weeks prior to starting on the TNF therapy.
Table 1 TICOPA Study inclusion and exclusion criteria
Inclusion criteria
1. Patients with a diagnosis of psoriatic arthritis by a consultant
Rheumatologist with less than 24 months disease duration
2. Active disease defined by at least one tender or swollen joint or
active enthesitis.
3. Age ≥18 years at the time of signing the informed consent form
and either male or female patients.
4. Patient understands the objectives of the study and is able and
willing to sign the Informed Consent Form.
5. Women of child bearing potential (WCBP) and men whose partners
are WCBP must use at least one adequate birth control measure
whilst receiving protocol treatment and should continue such
precautions after receiving the last dose of protocol treatment as
indicated in the relevant SmPC.
6. Adequate full blood count within 28 days before randomisation:
a. Haemoglobin count > 8.5 g/dL
b. White blood count (WBC) > 3.5 × 109/L
c. Absolute neutrophil count (ANC) > 1.5 × 109/L
d. Platelet count > 100 × 109/L
7. Adequate hepatobiliary function within 28 days before
randomisation:
a. ALT and/or AST levels must be within 3 times the upper limit of
normal range (ULN) for the laboratory conducting the test.
8. The patient must be able to adhere to the study visit schedule and
other protocol requirements.
Exclusion criteria
1. Previous treatment for articular disease with disease modifying drugs
(DMARDs) including, but not limited to, methotrexate, sulfasalazine,
leflunomide.
2. Women who are pregnant, lactating or planning pregnancy within
6 months of their last dose of protocol treatment.
3. Use of any investigational agents within 4 weeks or within 5 half-
lives of the investigational agent, whichever is longer, prior to
randomisation.
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for a minimum of 3 months whilst anti-TNF therapy is
given.
Patient follow-up procedures
Patients will be treated in the trial for a period of 48
weeks and followed up for a further 4 weeks. Patients in
the intensive management arm will attend the tight con-
trol clinic every 4 weeks. For patients in the standard
care arm, they will attend a general NHS rheumatology
clinic according to local practice dictated by the treating
physician, which is usually every 12 weeks.
Patients will be followed up from the baseline assess-
ment to 52 weeks post start of treatment. Follow up as-
sessments will involve a full clinical assessment at 12
weekly intervals to 48 weeks; entailing a physical exam-
ination, a full clinical disease assessment, concomitant
medical history, and obtainment of safety and efficacy
bloods. The follow-up assessment will be performed by aresearch nurse or metrologist blinded to the allocated
treatment group. A final safety assessment will then be
conducted at 52 weeks. Where possible, trial clinical as-
sessments will be performed at the same visit as the
treatment clinic visits.
Patients who have consented to the imaging sub-study
will undergo additional imaging assessments (ultrasound,
peripheral MRI and high-field MRI) of peripheral joints
and entheses.
Cessation or alteration of treatment regimes will be at
the discretion of the clinician or the patient. All patients
withdrawn from treatment or prescribed alternative
treatment will still attend for follow-up assessments to
the end of the study unless the patient withdraws con-
sent for follow-up.
As all therapies are routinely used in the care of PsA,
we expect that patients will continue on their medi-
cation as long as response has been demonstrated. All
patients will be offered continuing follow up in the most
appropriate rheumatology clinic at their site after the
patient completes the study (a specialised PsA clinic
where available).
Outcome measures
The primary endpoint of the study is achievement of
American College of Rheumatology (ACR) 20 response
at 48 weeks. The ACR20 is a composite response meas-
ure developed for RA and requires an improvement of
at least 20% in tender and swollen joint counts and a
20% improvement in three out of five criteria from base-
line to 48 weeks: (i) patient global assessment of disease
activity (VAS); (ii) physician global assessment of disease
activity (VAS); (iii) patient assessment of pain (VAS); (iv)
Health Assessment Questionnaire (HAQ), and (v) an in-
flammatory marker (Erythrocyte Sedimentation Rate
(ESR) or C-reactive Protein (CRP)) [14]. This has now
been validated as a discriminative outcome measure in
PsA [15].
Key secondary endpoints at 48 weeks are: (i) ACR50
and ACR70; (ii) Psoriasis Area Severity Index (PASI) 75;
and (iii) modified X-ray Van der Heijde score; and also
the cost effectiveness ratio using quality adjusted life
year (QALY) outcome measures at 12, 24 and 48 weeks.
The additional secondary endpoints at 24 weeks are (i)
ACR20, ACR50 and ACR70 at 24 weeks; (ii) PASI75;
and then at 24 and 48 weeks: (iii) ASAS20, ASAS40;
(iv) Leeds Enthesitis Index [16,17]; (v) dactylitis score
(using the Leeds Dactylitis Instrument); (vi) modified
Nail Psoriasis Severity Index (mNAPSI); (vii) HAQ;
(viii) PsAQoL; (ix) BASDAI 50; (x) tender and swollen
joint counts; (xi) the physician’s assessment of overall
disease activity, (xii) the patient’s assessment of global
disease activity and pain; (xiii) achievement of minimal
disease activity (MDA) criteria; (xiv) radiographic joint
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Heijde score, and (xv) overall safety.
For the imaging subgroup, endpoints relating to inflam-
mation (ultrasound synovitis, MRI inflammation) and dam-
age (bone erosion or damage on ultrasound or MRI) will be
measured at baseline and at 48 weeks.
Sample size calculations
The primary outcome of the study is the proportion of
patients who achieve an ACR20 response at 48 weeks.
Previous data for patients with PsA [18] has shown
ACR20 at 3 and 6 months to be 50% and 43% respect-
ively. As it was expected that this patient group had a
poorer prognosis we have therefore assumed that the
proportion of patients achieving ACR20 in the standard
care arm will be approximately 50% at 48 weeks. An ab-
solute difference in ACR20 rates of 20% has been
deemed to be a clinically significant difference. There-
fore, with 80% power and based on a chi-squared test
without continuity at the 2-sided 5% significance level,
93 patients per arm (186 patients in total) are required
to detect an increase in ACR20 rates of 20%. To allow
for a 10% drop-out rate, 206 patients will be recruited.
Statistical analysis
An intention-to-treat analysis will be the primary method
for analysing and summarising the study data. Patients will
be analysed according to the management pathway they
were randomised to receive. All formal analyses will be
carried out at a 2-sided 5% level of significance.
Primary endpoint analysis
For the primary endpoint analysis, treatment groups will
be compared by fitting a logistic regression model to
response (whether the patient achieved ACR20 at 48
weeks) adjusted for the minimisation factors arthritis
classification and centre. Treatment and covariate esti-
mates and odds ratios with corresponding 95% con-
fidence intervals (CIs) will be presented, along with the
p-values. In addition the difference in the proportion of
patients achieving an ACR20 response will be presented,
with corresponding 95% CIs, and compared using a chi-
squared test without continuity correction. Multiple im-
putation will be used to impute missing primary endpoint
data. Sensitivity analyses will be performed in order to
assess the consistency of the final conclusions and robust-
ness of the ITT population with missing data imputed by
multiple imputation.
A repeated measures analysis will also be performed on
the primary endpoint in order to assess ACR20 response
over the duration of the study. A multi-level repeated
measures model will be used to compare ACR20 scores
between treatment groups, adjusted for the minimisationfactors. Summary statistics at each follow-up time-point
will be presented.
Key secondary endpoint analysis
Logistic regression adjusting for the minimisation fac-
tors, will be used to compare the ACR50, ACR70 and
PASI75 between treatment arms at 48 weeks.
All additional secondary endpoints will be summarised
descriptively by treatment group and time point. No
formal statistical testing will be carried out on these
endpoints.
Safety analyses will summarise all serious adverse
events, suspected unexpected serious adverse events,
adverse events, pregnancies and deaths, and will be
presented by treatment group and overall.
Economic evaluation
The economic evaluation will assess cost effectiveness
using within trial incremental cost effectiveness ratios;
the costs and benefits of intensive management to the
costs and benefits of usual care over trial duration. Ana-
lysis will use overall survival and quality adjusted life
years (QALYs) outcome measures. Sensitivity analysis of
the incremental cost effectiveness ratio will be under-
taken. A scatter plot on the cost effectiveness plane, the
95% cost effectiveness elipse and the cost effectiveness
acceptability curve will be presented.
Discussion
PsA is a common and disabling disease but it has re-
ceived less attention than RA in both clinical and trans-
lational research. Evidence from RA has identified the
link between inflammation and subsequent joint dam-
age, leading to an emphasis on early aggressive treat-
ment to reduce joint inflammation causing less joint
damage and improved outcome. However, the relation-
ship between inflammation and damage has not been
well studied in PsA. Observational studies have shown
that swollen joints often subsequently become damaged
on X-rays and studies using new, highly effective anti-
inflammatory therapies in PsA have shown improvement
in disease activity in association with a reduction in
levels of joint damage over time. Observational cohort
data from Toronto has shown that patients presenting
to clinic with less than two years disease duration fared
better than those presenting later in terms of ongoing
progressive joint damage, despite controlling for baseline
joint damage [12]. Together, this body of research sug-
gests that a similar ‘tight control’ treatment strategy
to that applied in RA may be successful in improving
outcomes in PsA. The TICOPA study aims to provide
evidence-based optimal treatment for people diagnosed
with PsA.
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ies to ensure that their joint inflammation is minimised,
will be assessed. It is expected that joint damage will be
reduced further in those patients treated intensively, there-
fore preventing disability. This therapeutic trial will provide
direct evidence to inform the use of early and intensive
treatment in PsA to ensure improvement in patients’ dis-
ease activity and a reduction in radiological joint damage.
In addition, the detailed imaging assessments used during
the study aims to advance our mechanistic understanding
of the relationships between inflammation, damage and
bony proliferation in PsA.
Evidence of the benefit of intensive treatment from the
TICOPA study should cause a similar shift in routine
practice to that seen in RA to provide superior clinical
care to patients with PsA.
Time plan for the TICOPA study
Patient recruitment began in May 2008 at one site
(Leeds Teaching Hospital NHS Trust); a total of 206 pa-
tients have been recruited across eight centres, and the
trial closed to recruitment on 21st March 2012. The trial
is currently in follow-up until March 2013.
Ethical consideration
Ethical and governance approval for this study has been
obtained from the Northern and Yorkshire Research
Ethics Committee (ref 07/H0903/72) and the Leeds
Teaching Hospitals NHS Trust respectively. The trial
progress is monitored by an independent Data Monitor-
ing and Ethics Committee (DMEC) and Trial Steering
Committee (TSC).
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